TreeFrog's Chief Scientific Officer & Co-founder, Maxime Feyeux, to present at The 23rd Congress of the Japanese Society for Regenerative Medicine (JSRM)

March 21, 2024 10:30 AM AEDT | By Cision
Follow us on Google News: https://kalkinemedia.com/resources/assets/public/images/google-news.webp

- TreeFrog Therapeutics demonstrates fast, sustained, full motor recovery in preclinical models for Parkinson's Disease cell therapy program using C-Stem™ proprietary technology[1] -  

BORDEAUX, France, March 21, 2024 /PRNewswire/ -- TreeFrog Therapeutics, a cell therapy development company with its lead program in Parkinson's Disease is today presenting their latest data in Parkinson's Disease, at the 23rd Congress of the Japanese Society for Regenerative Medicine, in Niigata, Japan.

Parkinson's Disease is the second most common neurodegenerative disease, caused by the progressive loss of neurons in the midbrain and other brain regions. Affecting 10 million people worldwide, it is a debilitating disease and there is an urgent unmet need as only symptomatic treatment is currently available. Symptoms usually appear when between 60-80% of dopaminergic neurons are already lost, so a regenerative medicine approach that can replace these neurons holds great potential.

TreeFrog Therapeutics unique approach uses induced pluripotent cells (iPSC) that are amplified exponentially and then differentiated into dopaminergic neurons in one closed system, using a proprietary platform, C-Stem™.  

"The preclinical results we are presenting demonstrate fast, sustained, full motor recovery at 8 months and we are excited to move towards the clinic. C-Stem ensures pluripotent stem cell amplification with 98% viability and maintains genomic integrity. Within the same system, we differentiate 3D neural microtissues containing mature dopaminergic neurons, which contrast with other cell therapy approaches based on the transplantation of single cell suspensions. The microtissue format has many benefits, including better reproducibility and a better-quality control as batch release is based on mechanism of action relevant dopamine quantification" explains Maxime Feyeux, Chief Scientific Officer, TreeFrog Therapeutics.

Details of the presentation

  • Title: Scaling-up iPSC-based cell therapies: real-world processes with biomimetic C-Stem technology
  • Session: Poster 9 "Nerves 1" / Presentation number: P-08-4
  • Date and time: March 21st (Thursday) 16:20-17:10
  • Venue: Poster venue at Toki Messe, 1F Exhibition Hall

TreeFrog Therapeutics is a biotech company set to unlock access to cell therapies for millions of patients. It brings together biophysicists, cell biologists and bioproduction engineers to address the challenges of the industry - producing and differentiating cells of quality at unprecedented scale, cost-effectively. To realize their mission of Cell Therapy for all, TreeFrog has both their own therapeutic programs and partnerships with leading biotech and industry players in other areas.

www.treefrog.fr

[1] Data on file. Poster P-08-4, Japan Society of Regenerative Medicine Annual Meeting 21st-23rd March 2024

CONTACT: [email protected]

 


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.

Two ASX Listed Stocks Giving Bullish Indications

Recent Articles

Investing Tips

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.